Hemogenyx Pharmaceuticals Share Discussion Threads

[apotheki] 17/2/2024 14:10

Sounds as though 2024 is going to be one hell of a year....

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.

Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options.

Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.

As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike.

Proactive interview::::

[dreamtwister] 17/2/2024 13:34

log that was 2017 since 5 car-t therapy's has been approved & numerous on c/h

the big question do you educate the immune system or programe the DNA cells ?

Has Dr sandler the missing Answer !

[loglorry1] 17/2/2024 13:27

Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) were the first two CAR-T products to be approved for the treatment of patients up to 25 years of age with refractory/relapsed B-cell precursor acute lymphoblastic leukemia (ALL) and adult patients with relapsed or refractory diffuse large B-cell lymphoma.


I think HEMO are way behind the curve here.

[dreamtwister] 17/2/2024 13:20

Hemogenyx will not be eligible to registrar on the data base until they enter the clinical trials.

listening again to the pro-active pod cast i can confirm that Dr sandler has stated the car-t

Clinical trials are a couple of months from progressing.

[loglorry1] 17/2/2024 12:29

hXxps://bioinformant.com/car-t-companies-the-meteoric-rise-of-cellular-immunotherapies/#burgeoning

Not a single mention of HEMO. Its all just an AIM promote. Shared directors with PIRI is a massive red flag.

[dreamtwister] 17/2/2024 10:09

Conclusion: the above post is Pure waffle,give it a slap with a wet kipper !

Here is a Fact:The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor !

an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration !

Here is the Fiction: Hemogenyx Cbr platform remains in the Petri Dish in Vivo unproven in Humans !

lets not let the Fiction over ride the Facts:phase11 of the clinical trial 153 patients of whom had
3 prior lines of therapy received Lifileuce these are very late line Patients that have exhausted
every standard care of options !

Eighteen months later Patients are still responding:

To summarize The Patients Harvest their own T CELLS.. this is a blessing as TIME is a very important
Factor Alleviating the lengthy Car-T Manufacturing Duration of ten days... & on a positive direction
of Acessibility & Afordability and most important the Health & Safety of Patients !

[master rsi] 16/2/2024 23:53

From another place by "reg" ..... for those who maybe are short, take care of your words going everewhere with the same sh!t

" Funding question Today 20:05
My view.....funding for CAR T trials with University of Penssylvania is in place if Hemo wish to take it..... Prevail Hemo have had months to finalise this investment on FDA approval.....So what is holding things up.....Maybe someone else is prepared to pay a lot more than 6 per share premium Prevail have historically offered.....or wants more equity in Hemos CAR T cell program....or indeed Hemo itself.....eg big Pharma offering 15 plus per share at this stage is not out of the question..... on early stage milestones.....Certain big Pharma players are playing catch up in the Holy Grail Oncology CAR T.....and prepared to pay hefty premium for the IP.....Conclusion....I believe Hemo are in play.....thats why the Ceo has put all his Aces....in the shop window....

[master rsi] 16/2/2024 23:39

Do not trust b@stards with 1 month around and being negative toxic

Tomavery19
Member since: 04 Jan 2024

[dreamtwister] 16/2/2024 17:09

correct me if i have misheard "has Dr Sandler confirmed the trials will commence

within the next couple of months...3.03 in



i thought the interview in relation to the car-t clinical trials was a bit Sparce ie how many patients are to be enrolled....previous lines of treatment/metabolismn...timeframes of ph1/11 trials ? prevail input.
collaboration/funding...ect.

[apotheki] 16/2/2024 16:55

HemoGenyx Pharmaceuticals / LSE:HEMO

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.

Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options.

Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.

As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike.

Proactive interview::::

[ries] 16/2/2024 10:45

Proactive interview.

[orchestralis] 16/2/2024 10:34

With 18m mcap, a large pharma could swoop in and take them out, just on the potential and patents.

[orchestralis] 16/2/2024 10:31

It's difficult to value as it doesn't have any revenue at present.

[everready1] 16/2/2024 10:30

strange such excellent news recently is not having the stellar effect on the share price! should be multiple of this derisory price

[jayrh] 16/2/2024 10:08

Waiting for funding before they allow it to go. Market is just corrupt manipulated to the teeth.

[ashleyjv] 16/2/2024 09:50

HEMO - We have discovered the Holy Grail of cancer treatment!
The market's reaction = Meh

[luckyabbeygale] 16/2/2024 09:00

Big buy trades confirm there will be no discounted placing. Any placing will be at a big premium like the 6p one was.

[apotheki] 16/2/2024 09:00

So adding September & November 2023 together a total of circa £1.25m was raised to add to the existing coffers.

One of those two fund raising was at a substantial premium which could potentially of course be replicated at some point!

[apotheki] 16/2/2024 08:55

18 September 2023

Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC

· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.
· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000). The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital.

The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners. Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study.

The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

[trying2trade] 16/2/2024 08:50

Hemo need to talk about the cash position before wasting this good news into uncertain investors.

[apotheki] 16/2/2024 08:15

Very early doors but the market appears to be struggling to keep up. There was a U/T @ 4p but otherwise trading appears to be all over the place!

[apotheki] 16/2/2024 08:10

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR into the brain is a unique tool that may allow us to successfully tackle some of the most difficult and often incurable human diseases. As we broaden the scope of use for our CBR platform, we are eager to continue its development."